A phase 1 trial of recombinant human acid sphingomyelinase (rhASM) enzyme replacement therapy in adults with ASM deficiency (ASMD)

Authors
Category Primary study
JournalMolecular Genetics and Metabolism
Year 2009
This article has no abstract
Epistemonikos ID: b3fb63bcc04bde297de705f62d3662a4a94cffa1
First added on: Feb 28, 2025